TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06688916

Intervention type: BEHAVIORAL
Intervention: Behavioral assessment
Description: A comprehensive behavioral assessment of embodiment and its effect on daily living, taking into account pain, interoception, emotions and anxiety, sleep quality, life satsfaction and cognition.

Intervention type: BEHAVIORAL
Intervention: Behavioral assessment
Description: A comprehensive behavioral assessment of embodiment and its effect on daily living, taking into account pain, interoception, emotions and anxiety, sleep quality, life satsfaction and cognition.

Intervention type: BEHAVIORAL
Intervention: Behavioral assessment
Description: A comprehensive behavioral assessment of embodiment and its effect on daily living, taking into account pain, interoception, emotions and anxiety, sleep quality, life satsfaction and cognition.

Intervention type: BEHAVIORAL
Intervention: Behavioral assessment
Description: A comprehensive behavioral assessment of embodiment and its effect on daily living, taking into account pain, interoception, emotions and anxiety, sleep quality, life satsfaction and cognition.

Intervention type: BEHAVIORAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Neural mechanisms of embodiments will be explored with MRI sequences including structural MRI, resting-state and task-based fMRI of the head.~The task will be a modified version of the rubber hand illusion, previously used to asess embodiment. Participants will be required to lay in the MRI with their legs bended upright and a screen placed at the level of their hips, which will show a pair of legs. The participant's leg will be stroked with a paintbrush while the image on the screen will be showing the virtual legs being stroked. Participants will be required to report how strongly they perceive the virtual legs as their own, as a measure of embodiment.

Intervention type: BEHAVIORAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Neural mechanisms of embodiments will be explored with MRI sequences including structural MRI, resting-state and task-based fMRI of the head.~The task will be a modified version of the rubber hand illusion, previously used to asess embodiment. Participants will be required to lay in the MRI with their legs bended upright and a screen placed at the level of their hips, which will show a pair of legs. The participant's leg will be stroked with a paintbrush while the image on the screen will be showing the virtual legs being stroked. Participants will be required to report how strongly they perceive the virtual legs as their own, as a measure of embodiment.
Study: NCT06686719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Facilitation
Description: For hamstring muscle, the patient positioned in supine with hip and knee flexed to mid- range. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 30 % of the strength for 15 seconds by attempting to push the leg back toward the therapist and relax. The therapist then passively stretched the muscle until a mild stretch sensation was reported. The stretch was held for another 10 seconds. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Isometric Relaxation
Description: For hamstring muscle, the patient positioned in supine with hip and knee flexed. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 25 % of the strength for 7-10 seconds by attempting to push the leg back toward the therapist and relax.After relaxation, the therapist further extends the knee for 3 to 5 seconds.. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release
Description: MFR for Hamstring muscle will be given with patient in prone position with 120 second hold. For giving the MFR, the thumb of the therapist will be allowed to sink in to the central portion of the hamstring. It will held for 120 seconds to allow the tissue to soften and then myofascial structures will spread in a lateral direction until feeling of first fascial barrier. MFR will be performed for 15 mins.~Stretching of the hip adductors, hip flexors and plantar flexors. Functional training includes kneeling, bridging and sit to stand.
Study: NCT06695559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labrida Bioclean
Description: Debridement on the active comparator group will be implemented on the implant surface with Labrida Bioclean (i.e. the chitosan brush).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Labrida Bioclean and tetracycline slurry
Description: On the experimental group debridement of the implant surface will be carried out with Labrida Bioclean and thereafter irrigation of the periimplant sulcus with tetracycline slurry will take place.
Study: NCT05583058

Intervention type: OTHER
Intervention: Hormone Overdose and Misuse
Description: This is an observational study. Hormone Overdose and Misuse is an exposure.
Study: NCT06461559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ileostomy infusion
Description: infusing patient's own ileostomy content into the diverted intestine
Study: NCT06132360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN0191
Description: This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN0191
Description: This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN0191
Description: This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN0191
Description: This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
Study: NCT05047627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-Based Digital Intervention
Description: The digital intervention will be a prototype, and the current trial will be used to continue to both develop and refine the intervention. The current intervention will be based on a combination of cognitive-behavioral principles. As with prior research, the mobile platform will be delivered via Qualtrics, a HIPAA compliant and mobile-friendly platform. The cognitive-behavioral therapy will be primarily based on components with strongest support in digital interventions. The app will continuously collect passive sensing data on patterns in 1) sleep duration and quality;(2) light (3) location; (4) movement (5) social contact including duration and frequency of incoming and outcoming calls and text messages; (6) screen time; and (7) heart rate variability; (8) sound levels captured through passively collected smartphone The platform will deliver interactive interventions where participants will view texts and images, and it will also allow user interaction.
Study: NCT05800015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Administered intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Administered intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Administered intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion, Q3W
Study: NCT04306315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Brodalumab
Description: Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.
Study: NCT06566313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: On the basis of conventional anti-PD drugs, the left M1 region (based on the C3 coordinates of EEG 10-20 system and the surrounding FC1, FC5, CP1, CP5 coordinates) was treated with cathodic tDCS. The electrical stimulation intensity was 2.0mA, the treatment time was 20min, and the treatment lasted for 10 days.
Study: NCT06160713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 65 MG
Description: Two capsules of suba-itraconazole 65 mg twice daily for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care for bronchiectasis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care for bronchiectasis
Study: NCT05523687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-PC14586
Description: Single, oral dose of \[14C\]-PC14586
Study: NCT05879510

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104 PET/CT
Description: Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
Study: NCT05800015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion, Q3W
Study: NCT05669885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be allocated to receive oral administration of placebo.
Study: NCT05625412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986360
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days
Study: NCT06488157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-HoME
Description: Video visits with a nurse practitioner for up to six visits every 2 weeks to address symptom management and care needs
Study: NCT05744232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie total diet replacement
Description: Summary~1. Weeks 1-12: TDR phase~2. Weeks 13-14: Food reintroduction phase I~3. Weeks 15-16: Food reintroduction phase II~4. Weeks 17 till 20: Food reintroduction phase III~5. Weeks 21 till 24: Maintenance phase

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded.
Study: NCT05931458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Appendectomy
Description: Laparoscopic appendectomy is a relatively simple surgical procedure that can be performedby most surgeons, either on an outpatient basis or with a single-night hospital stay. The laparoscopic approach is now the recommended option due to faster recovery times and fewer wound complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Administration of Infliximab (Anti-TNF-a biologic drug)
Study: NCT05860400

Intervention type: BEHAVIORAL
Intervention: Healthy life style
Description: Healthy diet, regular exercise, and quitting smoking

Intervention type: BEHAVIORAL
Intervention: Healthy life style
Description: Healthy diet, regular exercise, and quitting smoking

Intervention type: DRUG
Intervention: Secondary prevention for atherosclerotic coronary artery disease
Description: Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose

Intervention type: DRUG
Intervention: Secondary prevention for atherosclerotic coronary artery disease
Description: Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose

Intervention type: DRUG
Intervention: Immunosuppressive therapy
Description: Glucocorticoids and/or immunosuppressive agents

Intervention type: PROCEDURE
Intervention: Coronary revascularization
Description: Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).

Intervention type: PROCEDURE
Intervention: Coronary revascularization
Description: Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).

Intervention type: DRUG
Intervention: Supportive therapies
Description: Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.

Intervention type: DRUG
Intervention: Supportive therapies
Description: Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
Study: NCT05516966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Administrated SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Administrated SC
Study: NCT06397339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTACT Program
Description: The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program

Intervention type: OTHER
Group type: OTHER
Intervention: INTACT Program
Description: The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program
Study: NCT05613972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Suicide and Trauma Therapy
Description: 12-week trauma therapy
Study: NCT05516966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Administrated SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administrated SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administrated SC
Study: NCT06183892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Sustained-release Capsules
Description: Immediate-release tacrolimus for at least 3 months after liver transplantation, and then convert to tacrolimus sustained-release capsules at a ratio of 1:1 to 1:1.2; Take the medicine once a day on an empty stomach in the morning.~(The specific medication plan is decided by the clinician according to the actual situation)
Study: NCT05219799

Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol Hydrochloride
Description: Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures

Intervention type: DRUG
Group type: OTHER
Intervention: Isoproterenol
Description: Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness

Intervention type: DRUG
Group type: OTHER
Intervention: Phentolamine Mesylate
Description: This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).

Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
Study: NCT05516966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administrated SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide Injection
Description: Administrated SC
Study: NCT05399134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Functional Foods
Description: Subjects will be provided with ABREP-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice served in a mixed meal.~ABREP-fortified bread: Anthocyanins are known to exert anti-diabetic effects through modulating digestion, glucose uptake, insulin secretion and sensitivity. Moreover, inhibitory effects of anthocyanins on various carbohydrases, including a-glucosidase and a-amylase have been widely reported.~Microfluidic co-flow noodles: Microfluidic technology is employed to design noodle-food structures consisting of a mix of soy protein isolate and alginate as gelling agents to offer a type of novel noodles with proteins and negligible carbohydrate content.~5ibrePlus™-fortified white rice: 5ibrePlus™ is a patented novel fibre grain product by Alchemy Foodtech Pte. Ltd (WO 2017/142477) with reduced GI. Its main constituents are insoluble resistant starch and soluble fibre.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Functional Foods
Description: Subjects will be provided with control function foods including white bread, beehoon noodles, and jasmine white rice served in a mixed meal.